Clinical Trial Update: Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF) [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating a triple immunosuppressive regimen (EC-MPS, basiliximab, and C2-monitored cyclosporine) in de novo renal transplant recipients at hig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• Basiliximab (basiliximab)
• Cyclosporine (C2-monitored) (cyclosporine)
• Enteric-coated Mycophenolate Sodium (EC-MPS) (mycophenolate sodium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplantation | Phase 4 | Status: COMPLETED